Provided by Tiger Trade Technology Pte. Ltd.

Arrowhead Pharmaceuticals

65.45
-0.8000-1.21%
Post-market: 65.450.00000.00%19:30 EDT
Volume:1.74M
Turnover:114.39M
Market Cap:9.22B
PE:-28.66
High:66.80
Open:66.80
Low:65.09
Close:66.25
52wk High:95.49
52wk Low:34.38
Shares:140.86M
Float Shares:122.00M
Volume Ratio:0.85
T/O Rate:1.43%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.2838
EPS(LYR):-0.0122
ROE:-55.21%
ROA:-8.10%
PB:19.80
PE(LYR):-5,367.83

Loading ...

Arrowhead Pharmaceuticals' sHTG Therapy Could Get FDA Approval by Q2 2027, RBC Says

MT Newswires Live
·
Aug 31

Arrowhead Pharmaceuticals Price Target Maintained with a $100.00/Share by RBC Capital

Dow Jones
·
Aug 31

Arrowhead Pharmaceuticals Posts ESC 2026 Investor Presentation on Shasta-3 and Shasta-4 Results

Reuters
·
Aug 31

Sector Update: Healthcare

MT Newswires Live
·
Aug 31

Arrowhead Pharmaceuticals' Plozasiran Meets Endpoints in Studies of Patients With Severe Hypertriglyceridemia

MT Newswires Live
·
Aug 31

Arrowhead Phase 3 SHASTA-3, SHASTA-4 studies met primary endpoints

TIPRANKS
·
Aug 31

Arrowhead Pharmaceuticals - Plozasiran Demonstrated Favorable Safety and Tolerability Profile in Phase 3 Studies

THOMSON REUTERS
·
Aug 30

Arrowhead Pharmaceuticals - to File Supplemental Nda with U.S. FDA by Year-End 2026 Using Priority Review Voucher

THOMSON REUTERS
·
Aug 30

Arrowhead Pharmaceuticals Presents Phase 3 Shasta-3 and Shasta-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia

THOMSON REUTERS
·
Aug 30

Arrowhead Pharma Director Michael S. Perry Disposes of 11,600 Shares for $1.01 Million

Reuters
·
Aug 21

Arrowhead announces availability of REDEMPLO for FCS in Germany

TIPRANKS
·
Aug 17

People Living with Familial Chylomicronaemia Syndrome (Fcs) in Germany Have Access to Redemplo® (Plozasiran) as a New Treatment Option to Reduce Triglycerides

THOMSON REUTERS
·
Aug 17

Arrowhead Pharmaceuticals Earnings Call Signals Confident Expansion

TIPRANKS
·
Aug 16

How Investors Are Reacting To Arrowhead Pharmaceuticals (ARWR) Soaring Sales But Deepening Losses

Simply Wall St.
·
Aug 11

Arrowhead price target raised to $120 from $115 at H.C. Wainwright

TIPRANKS
·
Aug 07

Analysts Are Bullish on These Healthcare Stocks: Arrowhead Pharmaceuticals (ARWR), Vera Therapeutics (VERA)

TIPRANKS
·
Aug 05

U.S. Research Roundup-Ametek, Ball Corp, McDonald's

Reuters
·
Aug 05

Arrowhead Pharmaceuticals (ARWR) Gets a Buy from Chardan Capital

TIPRANKS
·
Aug 05

Arrowhead Publishes Transcript of Fiscal 2026 Third-Quarter Conference Call

Reuters
·
Aug 05

Arrowhead Pharmaceuticals Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 05